Your browser doesn't support javascript.
loading
DNA-PK Inhibitor Peposertib Amplifies Radiation-Induced Inflammatory Micronucleation and Enhances TGFß/PD-L1 Targeted Cancer Immunotherapy.
Carr, Michael I; Chiu, Li-Ya; Guo, Yige; Xu, Chunxiao; Lazorchak, Adam S; Yu, Huakui; Qin, Guozhong; Qi, Jin; Marelli, Bo; Lan, Yan; Sun, Qing; Czauderna, Frank; Zenke, Frank T; Blaukat, Andree; Vassilev, Lyubomir T.
Afiliación
  • Carr MI; Translational Innovation Platform Oncology and Immuno-Oncology, EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts.
  • Chiu LY; Translational Innovation Platform Oncology and Immuno-Oncology, EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts.
  • Guo Y; Translational Innovation Platform Oncology and Immuno-Oncology, EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts.
  • Xu C; Translational Innovation Platform Oncology and Immuno-Oncology, EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts.
  • Lazorchak AS; Translational Innovation Platform Oncology and Immuno-Oncology, EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts.
  • Yu H; Translational Innovation Platform Oncology and Immuno-Oncology, EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts.
  • Qin G; Translational Innovation Platform Oncology and Immuno-Oncology, EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts.
  • Qi J; Translational Innovation Platform Oncology and Immuno-Oncology, EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts.
  • Marelli B; Translational Innovation Platform Oncology and Immuno-Oncology, EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts.
  • Lan Y; Translational Innovation Platform Oncology and Immuno-Oncology, EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts.
  • Sun Q; Translational Innovation Platform Oncology and Immuno-Oncology, EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts.
  • Czauderna F; Translational Innovation Platform Oncology and Immuno-Oncology, EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts.
  • Zenke FT; Translational Innovation Platform Oncology and Immuno-Oncology, Merck KGaA, Darmstadt, Germany.
  • Blaukat A; Translational Innovation Platform Oncology and Immuno-Oncology, Merck KGaA, Darmstadt, Germany.
  • Vassilev LT; Translational Innovation Platform Oncology and Immuno-Oncology, EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts.
Mol Cancer Res ; 20(4): 568-582, 2022 04 01.
Article en En | MEDLINE | ID: mdl-34980594
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Inhibidores de Proteínas Quinasas / Neoplasias Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Mol Cancer Res Asunto de la revista: BIOLOGIA MOLECULAR / NEOPLASIAS Año: 2022 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Inhibidores de Proteínas Quinasas / Neoplasias Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Mol Cancer Res Asunto de la revista: BIOLOGIA MOLECULAR / NEOPLASIAS Año: 2022 Tipo del documento: Article Pais de publicación: Estados Unidos